13 results about "CD44" patented technology

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

The present invention relates to anti-CD44 antibodies that bind CD44 at the C-terminal part of the extracellular domain in an O-glycosylation dependent manner. Thereby, the antibodies are specific for tumor-associated CD44. The present invention also provides pharmaceutical compositions containing these anti-CD44 antibodies and their use in the treatment of cancer.

This invention provides the application of SPP1 or SPP1-positive macrophages as biomarkers in the preparation of diagnostic reagents for chronic gouty arthritis. It also provides the application of SPP1 or SPP1-CD44 signaling axis inhibitors in the preparation of drugs for the prevention and / or treatment of chronic gouty arthritis. This invention is the first to utilize SPP1... + Macrophages are key biomarkers and therapeutic targets for the chronicity of gout. Through single-cell and spatial transcriptomics technologies, we systematically analyzed their functional network in the microenvironment of tophi, providing a new direction for clinical prediction and intervention.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

The application relates to the field of health assessment, and particularly discloses a ZNF281-based gastric cancer prognosis value evaluation system, which comprises a ZNF281 expression quantification module, which is used for detecting the protein / RNA expression level of ZNF281 in tumor tissue through immunohistochemistry, real-time fluorescent quantitative PCR or Western blot technology; a stemness feature and signal path analysis module, which is used for acquiring the protein expression or cell positive rate of stemness genes CD44 and SOX9; then evaluating the activation state of an IL6 / JAK / STAT3 path, including Western blot detection of a p-STAT3 / STAT3 ratio, ELISA determination of IL6 and CXCL5 cytokine levels; then analyzing the cancer-associated fibroblast infiltration in a tumor microenvironment, quantifying the CAF density through alpha-SMA immunofluorescence staining, and combining single-cell sequencing analysis of the interaction strength of a CXCL5 / CXCR2 signal shaft. The technical scheme of the application can integrate the expression amount of ZNF281, signal path activity and clinical pathological data, and precisely stratify the chemotherapy sensitivity and prognosis of gastric cancer patients.

Provided is a method for screening polypeptides that specifically target T cells, comprising: providing T cells having a surface antigen marker selected from at least one of CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L), CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7; and contacting the T cells with a polypeptide display library, and screening therefrom target polypeptides that specifically bind to the T cells.

This specification discloses compositions comprising peptides containing a CD44 binding site and / or a calcium binding site, and a method for stimulating hair growth using said compositions.

The application discloses a kind of drug composition for pancreatic cancer liver metastasis under the background of metabolism-related fatty liver disease and preparation method and application thereof, the drug composition is with double-layer fat molecule spherical liposome as carrier, photosensitizer is loaded in the bilayer of liposome, chemotherapeutic drug gemcitabine is loaded in the cavity of liposome, gene therapy drug SiRNA CD44 is adsorbed on the surface of liposome.The GIR-Lip of the application can realize controllable killing and immune activation of tumor under laser irradiation, efficiently silence the high invasion and migration ability of CD44 tumor cells, combined with the first-line chemotherapeutic drug gemcitabine for pancreatic cancer, can ensure the combined effect, make up the drug resistance and curative effect loss caused by long-term use of gemcitabine.

The application provides a polylysine nanomaterial for oxaliplatin transmission and a preparation method thereof, and relates to the technical field of biopharmacy. The synthesis method has clear synthesis route and strong controllability. Through modular design, alkynyl hyaluronic acid, azide polylysine-vitamin E succinate and MMP enzyme sensitive peptide segment connector are prepared in sequence, and finally, click chemistry is used for efficient coupling. The product has clear structure, high purity and good batch reproducibility, and overcomes the problems of low coupling efficiency and many by-products in traditional methods. The prepared drug has the abilities of active targeting and double response drug release. The hyaluronic acid can specifically recognize the CD44 receptor highly expressed on the surface of tumor cells to realize active targeting. The MMP enzyme sensitive peptide segment can be cleaved by the overexpressed MMP-9 enzyme in the tumor microenvironment to realize enzyme response drug release. Meanwhile, the disulfide bond structure introduced in the carrier can be broken in the high concentration glutathione environment to realize reduction response drug release.

The invention discloses a biomarker of amyotrophic lateral sclerosis. On the first aspect, the invention provides application of a substance for detecting a biomarker in preparation of a diagnostic product for amyotrophic lateral sclerosis, and the biomarker comprises at least one of Lyz2, Mup20, Lgals3, Sfn, Apod, Apoe, C1QA, C1QB, SPA3N, CD44 and MT2. According to the scheme, proteomics detection is carried out on medulla oblongata and spinal cord areas of ALS mice and WT mice, a spinal cord and medulla oblongata differential protein network of an ALS pathological model is established, potential biomarkers are screened out, and ALS diagnosis is facilitated through research on the biomarkers.

The application discloses preparation and application of intelligent response nanoprobes based on manganese sulfide, and the nanoprobes are water-soluble and size-controllable HAMnS nanoparticles coated / chelated with hyaluronic acid as a surface functional layer, and near-infrared fluorescent dyes are loaded on the surface of the nanoparticles through electrostatic interaction and coordination / amide coupling to construct pH / ROS double-lock response "OFF-ON" fluorescent photoacoustic magnetic resonance multi-modal nanoprobes. In the physiological neutral and low ROS circulation, the dyes are in a fluorescence quenching state due to the close distance / accumulation / electron transfer with the MnS surface, so that the background is extremely low; when the probes are enriched in the tumor / inflammatory / metastatic lymph node and other lesion microenvironments through EPR effect and HA-mediated CD44 targeting, weak acidity induces MnS degradation and combines with ROS oxidation / ligand replacement to release free dyes or eliminate quenching, so that strong near-infrared fluorescence is lighted up; the change of component density provides a photoacoustic tracking signal, so that intraoperative real-time navigation and accurate boundary judgment from the molecular level to anatomical positioning are realized.